Tag: Sex

Producers Return With AI Audience-Tested Original Film Slate Projected $1.6B Gross RevenueVENTURA, Calif., Oct. 16, 2026 /PRNewswire/ -- Overactive Imagination Pictures, LLC (OIP) has...

Together, the inaugural reports can help inform decisions by offering data-driven insights into residency recruitment, matching, and pathways to physician training. WASHINGTON, Oct. 14,...

LAS VEGAS, Oct. 14, 2026 /PRNewswire/ -- The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through...

Natural Cycles expands clinical research, medical education, and consumer awareness to support growing demand for digital contraception in CanadaSTOCKHOLM, Oct. 7, 2026 /CNW/ --...

THCA flower for sale at Exhale Wellness: shop new exotic indoor-grown strains for 2026, lab-tested and Farm Bill-compliant. Buy premium hemp buds online.

Quantum AI Microcities Project Launch First Global AGI Communities Clinical Trial Network (Veterans First for America)

Exhale Wellness 2026 survey: 70% of THCA pre-roll buyers cite convenience as shoppers move from loose flower to lab-tested, ready-to-smoke hemp pre-rolls.

Leading Reproductive Agency Highlights Specialized LGBTQIA+ Family-Building Programs, Including Gestational Surrogacy, IVF Coordination, and Safe HIV Surrogacy via Advanced Sperm WashingLos Angeles, June 22,...

LOS ANGELES, June 17, 2026 /PRNewswire/ -- If you've ever finished sex and thought "that was fine" while knowing, somewhere deeper, that it wasn't...

HILLSBOROUGH, N.C., June 16, 2026 /PRNewswire/ -- In honor of National Sex Education Month and as part of its expanding commitment to sexual health...

Landsbankinn lauk í dag sölu á víkjandi forgangsbréfum (e. senior non-preferred bond) með breytilegum vöxtum að fjárhæð 250 milljónir norskra króna. Skuldabréfin eru til sex ára og með heimild til innköllunar að fimm árum liðnum (6NC5). Útgáfukjör miðast við 125 punkta álag á þriggja mánaða millibankavexti í norskum krónum.

COPENHAGEN, Denmark, June 13, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced Week 182 data from its completed Phase 3 PaTHway Trial showing that long-term treatment with TransCon PTH (palopegteriparatide) demonstrated sustained efficacy and safety in adults with hypoparathyroidism. Over the three-and-a-half-year duration of the trial, TransCon PTH replicated the systemic actions of endogenous PTH, with a balanced, beneficial impact on the main target organ systems – CNS, kidney, small intestine, and bone – as demonstrated by improved quality of life and normalized and stable urine calcium, serum calcium, serum phosphate, and bone mineral density. These benefits were sustained while enabling independence from conventional therapy with active vitamin D and calcium.

 -- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in hyperphagia and anxiety measures --   

-- Positive results reinforce rationale for Phase 3 development of MC4R agonism in PWS --

Horsewood supplement evaluated: 7-herb botanical male vitality formula, NCCIH research context, and 60-day money-back guarantee.